Strainprint Technologies Continues to Grow its Network of Medical Cannabis Subscribers with the Addition of WeedMD

Published: December 2, 2019

Strainprint Technologies Continues to Grow its Network of Medical Cannabis Subscribers with the Addition of WeedMD

StrainprintR Technologies Ltd, a cannabis data and analytics welcomed WeedMD Inc. to its growing portfolio of cannabis-based subscribers.

WeedMD is a federally-licensed producer and distributor of cannabis products for both the medical and adult-use markets. The company owns and operates a 158-acre greenhouse and outdoor facility located in Strathroy, ON and CX Industries, a wholly-owned subsidiary of WeedMD Inc. operating out of the Company’s fully-licensed 26,000 sq. ft. Aylmer, Ontario production facility. WeedMD’s annual greenhouse cannabis production capacity is more than 20,000 kgs, with an approximately 20,000 kgs more of incremental biomass currently being harvested from its 27-acre outdoor cultivation platform in Strathroy.

“Our goal in working with Strainprint is to continue to drive transparency and data-driven efficacy in the cannabis industry. Leveraging Strainprint’s technology, we can ensure that our top-quality cannabis products make it to the market in a secure and reliable manner,” said Brett Moon, Senior Vice President of Sales and Marketing, WeedMD. “We aim to consistently provide a portfolio of medical-grade cannabis products, leveraging Strainprint’s real-time patient data and analytics to determine the most effective medical and recreational strains for cultivation and distribution.”

The fast-growing company will have access to the Strainprint Analytics web platform, the most sophisticated cannabis analytics platform available, to identify patterns for the products cultivated, processed or distributed, ultimately improving overall product development for optimal treatment options. Strainprint Analytics is built on top of the world’s largest real-time observational study of medical cannabis patients, with more than 1.4 million anonymized, patient reported outcomes and more than 70 million data points on strain efficacy.

“We’re thrilled to extend our suite of real-time technology services to organizations who share our goal to change the status quo in the cannabis industry,” said Strainprint CEO, Andrew Muroff. “With companies like WeedMD we aim to help personalize medical cannabis by helping people select the best cannabis products to suit their specific needs, using data and analytics.”

For more information visit www.strainprintanalytics.com and https://www.weedmd.com/.

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).

 

Read Article